Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2010

View Archived Issues

Takeda reviews first half of fiscal year 2010

Reticulon-4 is a putative biomarker and inducer of pathogenesis in PAH

Tasocitinib leads to sustained improvement in patients with rheumatoid arthritis

First-in-human data presented on RO-5126766 in advanced/metastatic solid tumors

AMG-557 dose-dependently blocks ICOS ligand on B cells in patients with SLE

PA-21 is safe and reduces hyperphosphatemia in subjects with CKD on hemodialysis

AnaptysBio begins to receive QTDP grants in support of four programs

Novo Nordisk reports R&D highlights of third quarter 2010

Boehringer Ingelheim claims new chemokine CXCR3 receptor antagonists

Axikin Pharma presents new chemokine CCR3 receptor antagonists

Institute for OneWorld Health claims new CFTR inhibitors

New oxalato complexes of platinum disclosed for treatment of cancer

Banyu Pharma patents new antagonists of peptide P518 receptor

Vexon divulges new peptide derivatives with analgesic activity

Nostrum Pharma and IMTECH enter license agreement in India for new thrombolytics

Health Canada approves Allergan's Restasis for dry eye disease

FDA clears Auris Medical's IND for phase II AM-101 trial in acute inner ear tinnitus

Auris Medical advances phase IIb trial of AM-111 in acute sensorineural hearing loss

Covidian licenses drug delivery platform technology from UBC and CDRD

Clavis Pharma secures capital to advance anticancer pipeline

FDA extends review period of cladribine tablets for relapsing forms of MS

Basilea and Astellas change primary endpoint for phase III isavuconazole trial in aspergillosis

Verona confirms delivery of RPL-554 by standard asthma inhaler devices

Beech Tree Labs closes financing and receives U.S. government grant

Compugen develops new platform to discover new members of protein families

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...